膀胱癌染色體及基因FISH檢測試劑盒
| 型 號： | |
| 報 價： |  |
膀胱癌染色體及基因FISH檢測試劑盒 膀胱癌的病因復(fù)雜，既有內(nèi)在的遺傳因素，又有外在的環(huán)境因素。較為明確的兩大致病危險因素是吸煙和職業(yè)接觸芳香胺類化學(xué)物質(zhì)。吸煙是目前Z為肯定的膀胱癌致病危險因素，30%～50%的膀胱癌由吸煙引起，吸煙可使膀胱癌危險率增加2～6倍，隨著吸煙時間的延長，膀胱癌的發(fā)病率也明顯增高。另一重要的致病危險因素是與一系列職業(yè)或職業(yè)接觸有關(guān)。
- 產(chǎn)品描述
膀胱癌染色體及基因FISH檢測試劑盒
廣州健侖生物科技?有限公司
本司長期供應(yīng)尼古?。商鎸帲z測試劑盒，其主要品牌包括美國NovaBios、廣州健侖、廣州創(chuàng)侖等進(jìn)口產(chǎn)品，國產(chǎn)產(chǎn)品，試劑盒的實驗方法是膠體金方法。
我司還有很多熒光原位雜交系列檢測試劑盒以及各種FISH基因探針和染色體探針等，。
人類該基因定位于染色體17q12，其編碼產(chǎn)物為185kD的跨膜精蛋白p185，由1255個氨基酸組成，720—987位屬于酪氨酸激酶區(qū)。Her-2/neu蛋白是具有酪氨酸蛋白激酶活性跨膜糖蛋白，是EGFR家族成員之一。
歡迎咨詢
歡迎咨詢
以下是我司出售的部分FISH產(chǎn)品：
| D13S25（13q14）探針（紅色） |
| JAK2（9p24）基因斷裂探針 |
| FRS2（12q15）基因探針 |
| p53/RB1/ATM/CSP12/D13S25/6/6q21/IGH基因探針(七探針 ) |
| MYC（8q24），BCL6（3q37），BCL2（18q21）探針 |
| API2/MALT1融合基因t(11;18)探針 |
| MALT1/IGH融合基因t(14;18)探針 |
| IGH融合基因（CCND1,MAF,MAFB,FGFR3）探針 |
| ALK、MET、ROS1基因探針 |
| FGFR1,PDGFRA,PDGFRB基因探針 |
| 7號/8號染色體探針 |
| 8號/17號染色體探針 |
| 8號染色體計數(shù)探針（紅色） |
| D7S522（7q31）基因探針 |
| RB1(13q14)/ATM(11q22)基因探針 |
| 12/D13S25基因探針 |
| p53/D13S319基因探針 |
| RB1/1q21基因探針 |
| 5q31(EGR1)基因探針 |
| BCL2（18q21）基因斷裂探針 |
| BCL6/IGH融合基因 t(3; 14) 探針 |
| KMT2A/AFF1融合基因t(4; 11) 探針 |
膀胱癌染色體及基因FISH檢測試劑盒我司還提供：登革熱，黃熱病，基肯孔熱，西尼羅河，立次克體，無形體，蜱蟲，恙蟲，錐蟲，利什曼原蟲，RK39, 漢坦病毒，乙腦，森林腦炎，寨卡病毒 ，H7N9 ,流感，霍亂，軍團(tuán)菌，結(jié)核，諾如病毒，輪狀病毒，炭疽，O157，葡萄球菌 ，流行性出血熱，傷寒桿菌，志賀氏菌檢測試劑,！
二維碼掃一掃
【公司名稱】 廣州健侖生物科技有限公司
【】 楊永漢
【】
【騰訊 】
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號二期2幢101-3室
【企業(yè)文化宣傳】
About 90% of patients with bladder cancer are initially diagnosed with hematuria. They are usually painless, intermittent, gross hematuria and sometimes hematuria. Hematuria may be only 1 or 1 days to several days, can be reduced or stopped, sometimes patients with hematuria often stop coincidence to patients was "illusion. Some patients may have hematuria again after a few periods of time apart. Blood urine stain from light red to dark brown, often dark red, the patient described it as washing water samples, tea water samples. The length of the amount of bleeding and the duration of hematuria is not necessarily proportional to the malignancy, size, range, and number of the tumor. Sometimes the tumor is very large or late in the hematuria, and sometimes a small tumor has a large amount of hematuria. Some patients found a tumor in the bladder when they were examined by B ultrasound during physical examination. 10% of the patients with bladder cancer can be the first symptoms of bladder stimulation, characterized by frequent urination and dysuria, urgency, dysuria, and patients without obvious hematuria. This is mostly due to tumor necrosis, ulceration, large or large number of bladder tumors, or diffuse bladder tumor infiltrating the bladder wall, resulting in decreased bladder volume or concurrent infection. The tumor of the bladder triangle and the neck of the bladder can obstruct the exportation of the bladder, with symptoms of difficulty in urination.
